hydrochlorothiazide has been researched along with Hyperuricemia in 16 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 8.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 7.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "The precise relationship of Hyperuricemia found in hypertensive patients is still obscure; this study is a urinary uric acid lowering intervention with Losartan in hypertensive patients induced by Thiazide diuretics." | 5.15 | To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. ( Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J, 2011) |
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| " Better understanding of the transporters URAT1 and ABCG2 in particular would appear to provide opportunities for more selective, better tolerated agents to increase the renal clearance of uric acid and thereby control hyperuricemia." | 4.90 | Uricosuric drugs: the once and future therapy for hyperuricemia? ( Bach, MH; Simkin, PA, 2014) |
| "We investigated serum uric acid changes and incident hyperuricemia in relation to the achieved blood pressure (BP) after 12 weeks of antihypertensive therapy with the irbesartan/hydrochlorothiazide combination." | 4.02 | Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. ( Huang, QF; Li, Y; Wang, JG; Zhang, D, 2021) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 3.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| " Potassium supplementation improves their insulin resistance and hypertension, whereas allopurinol reduces serum levels of uric acid and ameliorates hypertension, hypertriglyceridemia, hyperglycemia, and insulin resistance." | 3.74 | Thiazide diuretics exacerbate fructose-induced metabolic syndrome. ( Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sirivongs, D; Srinivas, TR, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.25) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, D | 1 |
| Huang, QF | 1 |
| Li, Y | 1 |
| Wang, JG | 1 |
| Ala-Mutka, EM | 1 |
| Rimpelä, JM | 1 |
| Fyhrquist, F | 1 |
| Kontula, KK | 1 |
| Hiltunen, TP | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Bach, MH | 1 |
| Simkin, PA | 1 |
| Vandell, AG | 1 |
| McDonough, CW | 1 |
| Gong, Y | 2 |
| Langaee, TY | 1 |
| Lucas, AM | 1 |
| Chapman, AB | 2 |
| Gums, JG | 2 |
| Beitelshees, AL | 2 |
| Bailey, KR | 1 |
| Johnson, RJ | 2 |
| Boerwinkle, E | 2 |
| Turner, ST | 2 |
| Cooper-DeHoff, RM | 2 |
| Johnson, JA | 2 |
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Wen, S | 1 |
| Zineh, I | 1 |
| Hall, K | 1 |
| Parekh, V | 1 |
| Ohshiro, K | 1 |
| Sakima, A | 1 |
| Nakada, S | 1 |
| Kohagura, K | 1 |
| Yamazato, M | 1 |
| Tana, T | 1 |
| Ohya, Y | 1 |
| Khan, M | 1 |
| Khan, RA | 1 |
| Islam, F | 1 |
| Laghari, J | 1 |
| Jamali, SN | 1 |
| Hosoya, T | 1 |
| Kuriyama, S | 1 |
| Ohno, I | 1 |
| Kawamura, T | 1 |
| Ogura, M | 1 |
| Ikeda, M | 1 |
| Ishikawa, M | 1 |
| Hayashi, F | 1 |
| Kanai, T | 1 |
| Tomonari, H | 1 |
| Soejima, M | 1 |
| Akaba, K | 1 |
| Tokudome, G | 1 |
| Endo, S | 1 |
| Fukui, A | 1 |
| Gomi, H | 1 |
| Hamaguchi, A | 1 |
| Hanaoka, K | 1 |
| Hara, Y | 2 |
| Hasegawa, T | 1 |
| Hayakawa, H | 1 |
| Hikida, M | 1 |
| Hirano, K | 1 |
| Horiguchi, M | 1 |
| Hosoya, M | 1 |
| Ichida, K | 1 |
| Imai, T | 1 |
| Ishii, T | 1 |
| Ishikawa, H | 1 |
| Kameda, C | 1 |
| Kasai, T | 1 |
| Kobayashi, A | 1 |
| Kobayashi, H | 1 |
| Kurashige, M | 1 |
| Kusama, Y | 1 |
| Maezawa, H | 1 |
| Maezawa, Y | 1 |
| Maruyama, Y | 1 |
| Matsuda, H | 1 |
| Matsuo, N | 1 |
| Matsuo, T | 1 |
| Miura, Y | 1 |
| Miyajima, M | 1 |
| Miyakawa, M | 1 |
| Miyazaki, Y | 1 |
| Mizuguchi, M | 1 |
| Nakao, M | 1 |
| Nokano, H | 1 |
| Ohkido, I | 1 |
| Ohtsuka, Y | 1 |
| Okada, K | 1 |
| Okamoto, H | 1 |
| Okonogi, H | 1 |
| Saikawa, H | 1 |
| Saito, H | 1 |
| Sekiguchi, C | 1 |
| Suetsugu, Y | 1 |
| Sugano, N | 1 |
| Suzuki, T | 2 |
| Takahashi, H | 1 |
| Takahashi, Y | 1 |
| Takamizawa, S | 1 |
| Takane, K | 1 |
| Morita, T | 1 |
| Takazoe, K | 1 |
| Tanaka, H | 1 |
| Tanaka, S | 1 |
| Terawaki, H | 1 |
| Toyoshima, R | 1 |
| Tsuboi, N | 1 |
| Udagawa, T | 1 |
| Ueda, H | 1 |
| Ueda, Y | 1 |
| Uetake, M | 1 |
| Unemura, S | 1 |
| Utsunomiya, M | 1 |
| Utsunomiya, Y | 1 |
| Yamada, T | 1 |
| Yamada, Y | 1 |
| Yamaguchi, Y | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Yokoyama, K | 1 |
| Yonezawa, H | 1 |
| Yoshida, H | 1 |
| Yoshida, M | 1 |
| Yoshizawa, T | 1 |
| OTTAVIANI, P | 1 |
| MANAI, G | 1 |
| MANDELLI, F | 1 |
| BORDONI, C | 1 |
| DOLCI, G | 1 |
| AYVAZIAN, JH | 1 |
| AYVAZIAN, LF | 1 |
| SMILO, RP | 1 |
| BEISEL, WR | 1 |
| FORSHAM, PH | 1 |
| SPERBER, RJ | 1 |
| FISCH, S | 1 |
| DEGRAFF, AC | 1 |
| FREUDENTHAL, RR | 1 |
| HEALEY, LA | 1 |
| MAGID, GJ | 1 |
| DECKER, JL | 1 |
| Reungjui, S | 1 |
| Roncal, CA | 1 |
| Mu, W | 1 |
| Srinivas, TR | 1 |
| Sirivongs, D | 1 |
| Nakagawa, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension[NCT03276598] | Phase 4 | 233 participants (Actual) | Interventional | 1999-11-25 | Completed | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Uric Acid and Hypertension in African Americans[NCT00241839] | Phase 3 | 150 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
"The Diastolic BP was taken at Baseline and after 8-10 weeks of treatment or placebo while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol / placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 3.44 |
| B (Placebo) | -0.83 |
Subjects had 24 hr blood pressure monitoring (ABPM) at baseline and treatment end. The readings were averaged and the changes from baseline to treatment end were compared. (NCT00241839)
Timeframe: Baseline and end of treatment (8-10 weeks on allopurinol / placebo)
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | -5.9 |
| B (Placebo) | 0.90 |
"The systolic BP was taken at Baseline and after 8-10 weeks of treatment on placebo, while on chlorthalidone and potassium chloride. The blood pressure was measured according to Shared Care protocol: 15 minutes of quiet, undisturbed rest with three BP measurements obtained subsequently at 5 minute intervals.~The mean of the second and third reading was the value used for analysis for both the Baseline measurement and the measurement after 8 - 10 weeks of treatment. The dependent variable is baseline value minus ending value.~Measures are in millimeters of mercury (mm hg)" (NCT00241839)
Timeframe: Measured at 8-10 weeks on allopurinol or placebo
| Intervention | mm Hg (Mean) |
|---|---|
| A (Allopurinol) | 0.21 |
| B (Placebo) | -0.95 |
Subjects on allopurinol are expected to lower their uric acid levels relative to placebo. (NCT00241839)
Timeframe: Baseline UA levels compared to end of treatment levels (8-10 weeks on allopurinol / placebo)
| Intervention | mg/dl (Mean) |
|---|---|
| A (Allopurinol) | 2.29 |
| B (Placebo) | 0.14 |
1 review available for hydrochlorothiazide and Hyperuricemia
| Article | Year |
|---|---|
Uricosuric drugs: the once and future therapy for hyperuricemia?
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Dis | 2014 |
3 trials available for hydrochlorothiazide and Hyperuricemia
| Article | Year |
|---|---|
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodiu | 2011 |
12 other studies available for hydrochlorothiazide and Hyperuricemia
| Article | Year |
|---|---|
Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination.
Topics: Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Humans; Hydrochlorothiazide; Hypertensi | 2021 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Effect of hydrochlorothiazide on serum uric acid concentration: a genome-wide association study.
Topics: Aged; Antihypertensive Agents; DNA-Binding Proteins; Female; Finland; Genome-Wide Association Study; | 2018 |
Hydrochlorothiazide-induced hyperuricaemia in the pharmacogenomic evaluation of antihypertensive responses study.
Topics: Adult; Antihypertensive Agents; Black or African American; Diuretics; Female; Genome-Wide Associatio | 2014 |
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Respons | 2011 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug | 2012 |
[Investigations of the mechanism of appearance of hyperuricemia caused by hydrochlorothiazide].
Topics: Chlorothiazide; Hydrochlorothiazide; Hyperuricemia; Kidney; Uric Acid | 1961 |
A study of the hyperuricemia induced by hydrochlorothiazide and acetazolamide separately and in combination.
Topics: Acetazolamide; Chlorothiazide; Humans; Hydrochlorothiazide; Hyperuricemia; Uric Acid | 1961 |
Reversal of thiazide-induced transient hyperuricemia by uricosuric agents.
Topics: Chlorthalidone; Humans; Hydrochlorothiazide; Hyperuricemia; Probenecid; Pyrazoles; Thiazides; Uric A | 1962 |
CORRECTION OF DIURETIC-INDUCED HYPOKALEMIA AND HYPERURICEMIA.
Topics: Bicarbonates; Blood Chemical Analysis; Chlorthalidone; Diuretics; Drug Therapy; Geriatrics; Hydrochl | 1965 |
Uric acid retention due to hydrochlorothiazide.
Topics: Chlorothiazide; Hydrochlorothiazide; Hyperuricemia; Uric Acid | 1959 |
Thiazide diuretics exacerbate fructose-induced metabolic syndrome.
Topics: Allopurinol; Animals; Blood Pressure; Body Weight; Diuretics; Fructose; Gout Suppressants; Hydrochlo | 2007 |